{"id":"r-mnhl-bfm-90","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Nausea and vomiting"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Hair loss"},{"rate":"5-20%","effect":"Infection"},{"rate":"5-15%","effect":"Anemia"}]},"_chembl":{"chemblId":"CHEMBL3663397","moleculeType":"Small molecule","molecularWeight":"414.51"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The regimen involves a combination of chemotherapy drugs, including methotrexate, cytarabine, and dexamethasone, which work together to kill cancer cells. The exact mechanism of action is not fully understood, but it is thought to involve the inhibition of DNA synthesis and cell division.","oneSentence":"R-mNHL-BFM-90 is a chemotherapy regimen used to treat certain types of non-Hodgkin lymphoma.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:31:04.799Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-Hodgkin lymphoma, particularly in children and young adults"}]},"trialDetails":[{"nctId":"NCT02842931","phase":"PHASE3","title":"R-Dose-adjusted (DA) - EPOCH-21 Versus R-modified Non-Hodgkin Lymphoma (NHL)-Berlin-Frankfurt-Munster (BFM)-90 Program (mNHL-BFM-90) and Autologous Stem Cells Transplantation (Auto-SCT) in DLBCL With Poor Prognosis","status":"UNKNOWN","sponsor":"National Research Center for Hematology, Russia","startDate":"2015-02","conditions":"Diffuse Large B-Cell Lymphoma","enrollment":300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"R-mNHL-BFM-90","genericName":"R-mNHL-BFM-90","companyName":"National Research Center for Hematology, Russia","companyId":"national-research-center-for-hematology-russia","modality":"Small molecule","firstApprovalDate":"","aiSummary":"The R-mNHL-BFM-90 is a treatment program for Diffuse Large B-Cell Lymphoma. It is a small molecule modality, as classified by ChEMBL.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}